Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 818107, 16 pages
http://dx.doi.org/10.1155/2014/818107
Review Article

Influence of Immune Responses in Gene/Stem Cell Therapies for Muscular Dystrophies

1Laboratorio Cellule Staminali, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Centro Dino Ferrari, Via F. Sforza 35, 20122 Milano, Italy
2Ystem s.r.l., Via Podgora 7, 20122 Milano, Italy

Received 27 January 2014; Revised 7 April 2014; Accepted 30 April 2014; Published 19 May 2014

Academic Editor: Fabio Rossi

Copyright © 2014 Andrea Farini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. E. H. Emery, “The muscular dystrophies,” British Medical Journal, vol. 317, no. 7164, pp. 991–995, 1998. View at Google Scholar · View at Scopus
  2. A. Bashir, Y.-T. Liu, B. J. Raphael, D. Carson, and V. Bafna, “Optimization of primer design for the detection of variable genomic lesions in cancer,” Bioinformatics, vol. 23, no. 21, pp. 2807–2815, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Gabellini, G. D'Antona, M. Moggio et al., “Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1,” Nature, vol. 439, no. 7079, pp. 973–977, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Gordon and P. R. Taylor, “Monocyte and macrophage heterogeneity,” Nature Reviews Immunology, vol. 5, no. 12, pp. 953–964, 2005. View at Google Scholar
  5. D. C. Guttridge, C. Albanese, J. Y. Reuther, R. G. Pestell, and A. S. Baldwin Jr., “NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1,” Molecular and Cellular Biology, vol. 19, no. 8, pp. 5785–5799, 1999. View at Google Scholar · View at Scopus
  6. J. G. Tidball and S. A. Villalta, “Regulatory interactions between muscle and the immune system during muscle regeneration,” American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 298, no. 5, pp. R1173–R1187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Arnold, A. Henry, F. Poron et al., “Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis,” Journal of Experimental Medicine, vol. 204, no. 5, pp. 1057–1069, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. V. A. Fadok, D. L. Bratton, L. Guthrie, and P. M. Henson, “Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: role of proteases,” Journal of Immunology, vol. 166, no. 11, pp. 6847–6854, 2001. View at Google Scholar · View at Scopus
  9. J. G. Tidball and M. Wehling-Henricks, “Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo,” Journal of Physiology, vol. 578, no. 1, pp. 327–336, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Gordon, “Alternative activation of macrophages,” Nature Reviews Immunology, vol. 3, no. 1, pp. 23–35, 2013. View at Google Scholar
  11. V. Horsley, K. M. Jansen, S. T. Mills, and G. K. Pavlath, “IL-4 acts as a myoblast recruitment factor during mammalian muscle growth,” Cell, vol. 113, no. 4, pp. 483–494, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. S. A. Villalta, H. X. Nguyen, B. Deng, T. Gotoh, and J. G. Tidbal, “Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy,” Human Molecular Genetics, vol. 18, no. 3, pp. 482–496, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. R. M. McDouall, M. J. Dunn, and V. Dubowitz, “Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy,” Journal of the Neurological Sciences, vol. 99, no. 2-3, pp. 199–217, 1990. View at Google Scholar · View at Scopus
  14. E. Gussoni, G. K. Pavlath, R. G. Miller et al., “Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy,” Journal of Immunology, vol. 153, no. 10, pp. 4798–4805, 1994. View at Google Scholar · View at Scopus
  15. J. R. Mendell, K. Campbell, L. Rodino-Klapac et al., “Dystrophin immunity in Duchenne's muscular dystrophy,” The New England Journal of Medicine, vol. 363, no. 15, pp. 1429–1437, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Farini, M. Meregalli, M. Belicchi et al., “T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse,” Journal of Pathology, vol. 213, no. 2, pp. 229–238, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Farini, C. Sitzia, C. Navarro et al., “Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model,” Experimental Cell Research, vol. 318, no. 10, pp. 1160–1174, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. J. Spencer, E. Montecino-Rodriguez, K. Dorshkind, and J. G. Tidball, “Helper (CD4+) and cytotoxic (CD8+) T cells promote the pathology of dystrophin-deficient muscle,” Clinical Immunology, vol. 98, no. 2, pp. 235–243, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. B. de Paepe and J. L. de Bleecker, “Cytokines and chemokines as regulators of skeletal muscle inflammation: presenting the case of Duchenne muscular dystrophy,” Mediators of Inflammation, vol. 2013, Article ID 540370, 2013. View at Publisher · View at Google Scholar
  20. P. Vandenabeele, L. Galluzzi, T. Vanden Berghe, and G. Kroemer, “Molecular mechanisms of necroptosis: an ordered cellular explosion,” Nature Reviews Molecular Cell Biology, vol. 11, no. 10, pp. 700–714, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Burzyn, W. Kuswanto, D. Kolodin et al., “A special population of regulatory T cells potentiates muscle repair,” Cell, vol. 155, no. 6, pp. 1282–1295, 2013. View at Google Scholar
  22. K. Nagaraju, R. Rawat, E. Veszelovszky et al., “Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B,” American Journal of Pathology, vol. 172, no. 3, pp. 774–785, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Rawat, T. V. Cohen, B. Ampong et al., “Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle,” American Journal of Pathology, vol. 176, no. 6, pp. 2891–2900, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Han and K. P. Campbell, “Dysferlin and muscle membrane repair,” Current Opinion in Cell Biology, vol. 19, no. 4, pp. 409–416, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Nagaraju, N. Raben, G. Merritt, L. Loeffler, K. Kirk, and P. Plotz, “A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli,” Clinical and Experimental Immunology, vol. 113, no. 3, pp. 407–414, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. A. M. Emslie-Smith, K. Arahata, and A. G. Engel, “Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies,” Human Pathology, vol. 20, no. 3, pp. 224–231, 1989. View at Google Scholar · View at Scopus
  27. N. Goebels, D. Michaelis, H. Wekerle, and R. Hohlfeld, “Human myoblasts as antigen-presenting cells,” Journal of Immunology, vol. 149, no. 2, pp. 661–667, 1992. View at Google Scholar · View at Scopus
  28. K. Arahata, T. Ishihara, H. Fukunaga et al., “Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses,” Muscle and Nerve, vol. 18, no. 2, pp. S56–S66, 1995. View at Google Scholar · View at Scopus
  29. T. L. Munsat, D. Piper, P. Cancilla, and J. Mednick, “Inflammatory myopathy with facioscapulohumeral distribution,” Neurology, vol. 22, no. 4, pp. 335–347, 1972. View at Google Scholar · View at Scopus
  30. R. Tawil, M. P. McDermott, S. Pandya et al., “A pilot trial of prednisone in facioscapulohumeral muscular dystrophy,” Neurology, vol. 48, no. 1, pp. 46–49, 1997. View at Publisher · View at Google Scholar
  31. S. Sookhoo, I. MacKinnon, K. Bushby, P. F. Chinnery, and D. Birchall, “MRI for the demonstration of subclinical muscle involvement in muscular dystrophy,” Clinical Radiology, vol. 62, no. 2, pp. 160–165, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Tasca, M. Pescatori, M. Monforte et al., “Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles,” PLoS ONE, vol. 7, no. 6, Article ID e38779, 2012. View at Google Scholar
  33. G. Frisullo, R. Frusciante, V. Nociti et al., “CD8+ T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI,” Journal of Clinical Immunology, vol. 31, no. 2, pp. 155–166, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Brunn, R. Schröder, and M. Deckert, “The inflammatory reaction pattern distinguishes primary dysferlinopathies from idiopathic inflammatory myopathies: an important role for the membrane attack complex,” Acta Neuropathologica, vol. 112, no. 3, pp. 325–332, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. M. R. Hussein, S. A. Hamed, M. G. Mostafa, E. E. Abu-Dief, N. F. Kamel, and M. R. Kandil, “The effects of glucocorticoid therapy on the inflammatory and Dendritic cells in muscular dystrophies,” International Journal of Experimental Pathology, vol. 87, no. 6, pp. 451–461, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. J. R. Mendell, L. Rodino-Klapac, Z. Sahenk et al., “Gene therapy for muscular dystrophy: lessons learned and path forward,” Neuroscience Letters, vol. 527, no. 2, pp. 90–99, 2012. View at Publisher · View at Google Scholar
  37. M. D. Grounds and J. Torrisi, “Anti-TNFα (Remicade) therapy protects dystrophic skeletal muscle from necrosis,” FASEB Journal, vol. 18, no. 6, pp. 676–682, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Hodgetts, H. Radley, M. Davies, and M. D. Grounds, “Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFα function with Etanercept in mdx mice,” Neuromuscular Disorders, vol. 16, no. 9-10, pp. 591–602, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. A. P. T. Taniguti, A. Pertille, C. Y. Matsumura, H. S. Neto, and M. J. Marques, “Prevention of muscle fibrosis and myonecrosis in mdxmice by suramin, a TGF-β1 blocker,” Muscle and Nerve, vol. 43, no. 1, pp. 82–87, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. C. van Erp, N. G. Irwin, and A. J. Hoey, “Long-term administration of pirfenidone improves cardiac function in mdx mice,” Muscle and Nerve, vol. 34, no. 3, pp. 327–334, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. E. P. Hoffman, D. Rao, and L. M. Pachman, “Clarifying the boundaries between the inflammatory and dystrophic myopathies: insights from molecular diagnostics and microarrays,” Rheumatic Disease Clinics of North America, vol. 28, no. 4, pp. 743–757, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. M. C. Walter, P. Reilich, S. Thiele et al., “Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial,” Orphanet Journal of Rare Diseases, pp. 8–26, 2010. View at Google Scholar
  43. A. Lerario, F. Cogiamanian, C. Marchesi et al., “Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy,” BMC Musculoskeletal Disorders, vol. 11, article 157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Nemoto, S. Konno, H. Sugimoto et al., “Anti-TNF therapy using etanercept suppresses degenerative and inflammatory changes in skeletal muscle of older SJL/J mice,” Experimental and Molecular Pathology, vol. 90, no. 3, pp. 264–270, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. O. Halevy, O. Genin, H. Barzilai-Tutsch et al., “Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone,” Histology and Histopathology, vol. 28, no. 2, pp. 211–2126, 2011. View at Google Scholar
  46. F. Mingozzi and K. A. High, “Immune responses to AAV vectors: overcoming barriers to successful gene therapy,” Blood, vol. 122, no. 1, pp. 23–36, 2013. View at Google Scholar
  47. A. Asokan, D. V. Schaffer, and R. J. Samulski, “The AAV vector toolkit: poised at the clinical crossroads,” Molecular Therapy, vol. 20, no. 4, pp. 699–708, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. Yi, M. J. Noh, and K. H. Lee, “Current advances in retroviral gene therapy,” Current Gene Therapy, vol. 11, no. 3, pp. 218–228, 2011. View at Google Scholar · View at Scopus
  49. A.-K. Zaiss, Q. Liu, G. P. Bowen, N. C. W. Wong, J. S. Bartlett, and D. A. Muruve, “Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors,” Journal of Virology, vol. 76, no. 9, pp. 4580–4590, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Li, N. Malani, S. R. Hamilton et al., “Assessing the potential for AAV vector genotoxicity in a murine model,” Blood, vol. 117, no. 12, pp. 3311–3319, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. A. K. Zaiss and D. A. Muruve, “Immunity to adeno-associated virus vectors in animals and humans: a continued challenge,” Gene Therapy, vol. 15, no. 11, pp. 808–816, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. B. Balakrishnan, D. Sen, S. Hareendran et al., “Activation of the cellular unfolded protein response by recombinant adeno-associated virus vectors,” PLoS ONE, vol. 8, no. 1, Article ID e53845, 2013. View at Google Scholar
  53. A. T. Martino, M. Suzuki, D. M. Markusic et al., “The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver,” Blood, vol. 117, no. 24, pp. 6459–6468, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Hareendran, B. Balakrishnan, D. Sen, S. Kumar, A. Srivastava, and G. R. Jayandharan, “Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them,” Reviews in Medical Virology, vol. 23, no. 6, pp. 399–413, 2013. View at Publisher · View at Google Scholar
  55. R. Han, E. M. Frett, J. R. Levy et al., “Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice,” Journal of Clinical Investigation, vol. 120, no. 12, pp. 4366–4374, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. A. K. Zaiss, M. J. Cotter, L. R. White et al., “Complement is an essential component of the immune response to adeno-associated virus vectors,” Journal of Virology, vol. 82, no. 6, pp. 2727–2740, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. G. C. Pien, E. Basner-Tschakarjan, D. J. Hui et al., “Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors,” Journal of Clinical Investigation, vol. 119, no. 6, pp. 1688–1695, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Li, M. Hirsch, A. Asokan et al., “Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo,” Journal of Virology, vol. 81, no. 14, pp. 7540–7547, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Li, N. Diprimio, D. E. Bowles et al., “Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles,” Journal of Virology, vol. 86, no. 15, pp. 7752–7759, 2012. View at Publisher · View at Google Scholar
  60. A. M. Maguire, F. Simonelli, E. A. Pierce et al., “Safety and efficacy of gene transfer for Leber's congenital amaurosis,” The New England Journal of Medicine, vol. 358, no. 21, pp. 2240–2248, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. W. W. Hauswirth, T. S. Aleman, S. Kaushal et al., “Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial,” Human Gene Therapy, vol. 19, no. 10, pp. 979–990, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. H. Jiang, D. Lillicrap, S. Patarroyo-White et al., “Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs,” Blood, vol. 108, no. 1, pp. 107–115, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. J. H. McIntosh, M. Cochrane, S. Cobbold et al., “Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine,” Gene Therapy, vol. 19, no. 1, pp. 78–85, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. B. A. Valentine, B. J. Cooper, A. de Lahunta, R. O'Quinn, and J. T. Blue, “Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies,” Journal of the Neurological Sciences, vol. 88, no. 1–3, pp. 69–81, 1988. View at Google Scholar · View at Scopus
  65. K. Yuasa, M. Yoshimura, N. Urasawa et al., “Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products,” Gene Therapy, vol. 14, no. 17, pp. 1249–1260, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Adriouch, E. Franck, L. Drouot et al., “Improved immunological tolerance following combination therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 muscle gene transfer,” Frontiers in Microbiology, vol. 2, p. 199, 2011. View at Publisher · View at Google Scholar
  67. S. Lorain, D.-A. Gross, A. Goyenvalle, O. Danos, J. Davoust, and L. Garcia, “Transient immunomodulation allows repeated injections of AAV1 and correction of muscular dystrophy in multiple muscles,” Molecular Therapy, vol. 16, no. 3, pp. 541–547, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. J. R. Mendell, L. R. Rodino-Klapac, X. Rosales-Quintero et al., “Limb-girdle muscular dystrophy type 2D gene therapy restores α-sarcoglycan and associated proteins,” Annals of Neurology, vol. 66, no. 3, pp. 290–297, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. B. C. Schnepp, K. R. Clark, D. L. Klemanski, C. A. Pacak, and P. R. Johnson, “Genetic fate of recombinant adeno-associated virus vector genomes in muscle,” Journal of Virology, vol. 77, no. 6, pp. 3495–3504, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Gregorevic and J. S. Chamberlain, “Gene therapy for muscular dystrophy—a review of promising progress,” Expert Opinion on Biological Therapy, vol. 3, no. 5, pp. 803–814, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. Z. Wang, T. Zhu, C. Qiao et al., “Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart,” Nature Biotechnology, vol. 23, no. 3, pp. 321–328, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Goyenvalle, A. Vulin, F. Fougerousse et al., “Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping,” Science, vol. 306, no. 5702, pp. 1796–1799, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. L. R. Rodino-Klapac, P. M. L. Janssen, C. L. Montgomery et al., “A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy,” Journal of Translational Medicine, vol. 5, article 45, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. R. E. Bittner, S. Shorny, B. Streubel, C. Hubner, T. Voit, and W. Kress, “Serum antibodies to the deleted dystrophin sequence after cardiac transplantation in a patient with Becker's muscular dystrophy,” The New England Journal of Medicine, vol. 333, no. 11, pp. 732–733, 1995. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Huard, R. Roy, J.-P. Bouchard, F. Malouin, C. L. Richards, and J.-P. Tremblay, “Human myoblast transplantation between immunohistocompatible donors and recipients produces immune reactions,” Transplantation Proceedings, vol. 24, no. 6, pp. 3049–3051, 1992. View at Google Scholar · View at Scopus
  76. J. P. Tremblay, F. Malouin, R. Roy et al., “Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy,” Cell Transplantation, vol. 2, no. 2, pp. 99–112, 1993. View at Google Scholar · View at Scopus
  77. A. Ferrer, K. E. Wells, and D. J. Wells, “Immune responses to dystrophin: implications for gene therapy of Duchenne muscular dystrophy,” Gene Therapy, vol. 7, no. 17, pp. 1439–1446, 2000. View at Google Scholar · View at Scopus
  78. E. Gussoni, H. M. Blau, and L. M. Kunkel, “The fate of individual myoblasts after transplantation into muscles of DMD patients,” Nature Medicine, vol. 3, no. 97, p. 970, 1997. View at Publisher · View at Google Scholar
  79. J. R. Mendell, J. T. Kissel, A. A. Amato et al., “Myoblast transfer in the treatment of Duchenne's muscular dystrophy,” The New England Journal of Medicine, vol. 333, no. 13, pp. 832–838, 1995. View at Publisher · View at Google Scholar · View at Scopus
  80. K. Yuasa, M. Sakamoto, Y. Miyagoe-Suzuki et al., “Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enchanced immune response against the transgene product,” Gene Therapy, vol. 9, no. 23, pp. 1576–1588, 2002. View at Publisher · View at Google Scholar · View at Scopus
  81. M. A. Khan, “Corticosteroid therapy in Duchenne muscular dystrophy,” Journal of the Neurological Sciences, vol. 120, no. 1, pp. 8–14, 1993. View at Publisher · View at Google Scholar · View at Scopus
  82. K. M. Flanigan, K. Campbell, L. Viollet et al., “Antidystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect,” Human Gene Therapy, vol. 24, no. 9, pp. 797–806, 2013. View at Publisher · View at Google Scholar
  83. N. A. Kootstra and I. M. Verma, “Gene Therapy with Viral Vectors,” Annual Review of Pharmacology and Toxicology, vol. 43, pp. 413–439, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. T. Kafri, U. Blomer, D. A. Peterson, F. H. Gage, and I. M. Verma, “Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors,” Nature Genetics, vol. 17, no. 3, pp. 314–317, 1997. View at Publisher · View at Google Scholar
  85. D. A. Rubinson, C. P. Dillon, A. V. Kwiatkowski et al., “lentivirus-based system to functionally silence genes in primary mammalian cellsstem cells and transgenic mice by RNA interference,” Nature Genetics, vol. 33, no. 3, pp. 401–406, 2003. View at Publisher · View at Google Scholar
  86. R. G. Amado and I. S. Y. Chen, “Lentiviral vectors—the promise of gene therapy within reach?” Science, vol. 285, no. 5428, pp. 674–676, 1999. View at Publisher · View at Google Scholar · View at Scopus
  87. J. P. Greelish, L. T. Su, E. B. Lankford et al., “Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector,” Nature Medicine, vol. 5, no. 4, pp. 439–443, 1999. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Li, D. Dressman, Y. P. Tsao, A. Sakamoto, E. P. Hoffman, and X. Xiao, “rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy,” Gene Therapy, vol. 6, no. 1, pp. 74–82, 1999. View at Publisher · View at Google Scholar · View at Scopus
  89. A. A. Hack, C. T. Ly, F. Jiang et al., “γ-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin,” The Journal of Cell Biology, vol. 142, no. 5, pp. 1279–1287, 1998. View at Publisher · View at Google Scholar · View at Scopus
  90. L. Cordier, A. A. Hack, M. O. Scott et al., “Rescue of skeletal muscles of γ-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer,” Molecular Therapy, vol. 1, no. 2, pp. 119–129, 2000. View at Publisher · View at Google Scholar · View at Scopus
  91. M. V. Neguembor and D. Gabellini, “In junk we trust: repetitive DNA, epigenetics and facioscapulohumeral muscular dystrophy,” Epigenomics, vol. 2, no. 2, pp. 271–287, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Bortolanza, A. Nonis, F. Sanvito et al., “AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy,” Molecular Therapy, vol. 19, no. 11, pp. 2055–2064, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. R. L. Boudreau, I. Martins, and B. L. Davidson, “Artificial MicroRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo,” Molecular Therapy, vol. 17, no. 1, pp. 169–175, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. D. Grimm, K. L. Streetz, C. L. Jopling et al., “Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways,” Nature, vol. 441, no. 7092, pp. 537–541, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. J. Meng, F. Muntoni, and J. E. Morgan, “Stem cells to treat muscular dystrophies—where are we?” Neuromuscular Disorders, vol. 21, no. 1, pp. 4–12, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Amit and J. Itskovitz-Eldor, “Derivation and spontaneous differentiation of human embryonic stem cells,” Journal of Anatomy, vol. 200, no. 3, pp. 225–232, 2002. View at Publisher · View at Google Scholar · View at Scopus
  97. M. K. Carpenter, E. Rosler, and M. S. Rao, “Characterization and differentiation of human embryonic stem cells,” Cloning and Stem Cells, vol. 5, no. 1, pp. 79–88, 2003. View at Google Scholar · View at Scopus
  98. L. M. Hoffman and M. K. Carpenter, “Characterization and culture of human embryonic stem cells,” Nature Biotechnology, vol. 23, no. 6, pp. 699–708, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. S. Bhagavati and W. Xu, “Generation of skeletal muscle from transplanted embryonic stem cells in dystrophic mice,” Biochemical and Biophysical Research Communications, vol. 333, no. 2, pp. 644–649, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. H. Kamochi, M. S. Kurokawa, H. Yoshikawa et al., “Transplantation of myocyte precursors derived from embryonic stem cells transfected with IGFII gene in a mouse model of muscle injury,” Transplantation, vol. 82, no. 4, pp. 516–526, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. K. Takahashi and S. Yamanaka, “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” Cell, vol. 126, no. 4, pp. 663–676, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. P. E. de Almeida, J. D. Ransohoff, A. Nahid, and J. C. Wu, “Immunogenicity of pluripotent stem cells and their derivatives,” Circulation Research, vol. 112, no. 3, pp. 549–561, 2013. View at Publisher · View at Google Scholar
  103. R.-J. Swijnenburg, S. Schrepfer, F. Cao et al., “In vivo imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation,” Stem Cells and Development, vol. 17, no. 6, pp. 1023–1029, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. T. Zhao, Z.-N. Zhang, Z. Rong, and Y. Xu, “Immunogenicity of induced pluripotent stem cells,” Nature, vol. 474, no. 7350, pp. 212–215, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. A. Mullally and J. Ritz, “Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation,” Blood, vol. 109, no. 4, pp. 1355–1362, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. Y. Mayshar, U. Ben-David, N. Lavon et al., “Identification and classification of chromosomal aberrations in human induced pluripotent stem cells,” Cell Stem Cell, vol. 7, no. 4, pp. 521–531, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. F. Cao, S. Lin, X. Xie et al., “In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery,” Circulation, vol. 113, no. 7, pp. 1005–1014, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Drukker, G. Katz, A. Urbach et al., “Characterization of the expression of MHC proteins in human embryonic stem cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 15, pp. 9864–9869, 2002. View at Publisher · View at Google Scholar · View at Scopus
  109. E. Goulmy, A. Termijtelen, B. A. Bradley, and J. J. van Rood, “Alloimmunity to human H-Y,” The Lancet, vol. 2, no. 7996, p. 1206, 1976. View at Google Scholar · View at Scopus
  110. G. Opelz, “Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies,” The Lancet, vol. 365, no. 9470, pp. 1570–1576, 2005. View at Publisher · View at Google Scholar · View at Scopus
  111. K. M. Dhodapkar, D. Feldman, P. Matthews et al., “Natural immunity to pluripotency antigen OCT4 in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 19, pp. 8718–8723, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. P. J. Fairchild, S. Cartland, K. F. Nolan, and H. Waldmann, “Embryonic stem cells and the challenge of transplantation tolerance,” Trends in Immunology, vol. 25, no. 9, pp. 465–470, 2004. View at Publisher · View at Google Scholar · View at Scopus
  113. S. Firner, L. Onder, V. Nindl, and B. Ludewig, “Tight control—decision-making during T cell-vascular endothelial cell interaction,” Frontiers in Immunology, vol. 3, p. 279, 2012. View at Google Scholar
  114. T. A. Partridge, J. E. Morgan, G. R. Coulton, E. P. Hoffman, and L. M. Kunkel, “Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts,” Nature, vol. 337, no. 6203, pp. 176–179, 1989. View at Google Scholar · View at Scopus
  115. D. Skuk and J. P. Tremblay, “Complement deposition and cell death after myoblast transplantation,” Cell Transplantation, vol. 7, no. 5, pp. 427–434, 1998. View at Publisher · View at Google Scholar · View at Scopus
  116. G. Benichou and V. H. Price, “T cell repertoire in mice with alopecia areata,” Journal of Investigative Dermatology Symposium Proceedings, vol. 4, no. 3, pp. 224–225, 1999. View at Google Scholar · View at Scopus
  117. H. Gudmundsdottir and L. A. Turka, “T cell costimulatory blockade: new therapies for transplant rejection,” Journal of the American Society of Nephrology, vol. 10, no. 6, pp. 1356–1365, 1999. View at Google Scholar · View at Scopus
  118. P. C. Nahirney, P. R. Dow, and W. K. Ovalle, “Quantitative morphology of mast cells in skeletal muscle of normal and genetically dystrophic mice,” The Anatomical Record, vol. 247, no. 3, pp. 341–349, 1997. View at Google Scholar
  119. G. M. Smythe, S. I. Hodgetts, and M. D. Grounds, “Immunobiology and the future of myoblast transfer therapy,” Molecular Therapy, vol. 1, no. 4, pp. 304–313, 2000. View at Publisher · View at Google Scholar · View at Scopus
  120. G. Karpati, D. Ajdukovic, D. Arnold et al., “Myoblast transfer in Duchenne muscular dystrophy,” Annals of Neurology, vol. 34, no. 1, pp. 8–17, 1993. View at Google Scholar · View at Scopus
  121. P. K. Law, T. G. Goodwin, Q. Fang et al., “Cell transplantation as an experimental treatment for Duchenne muscular dystrophy,” Cell Transplantation, vol. 2, no. 6, pp. 485–505, 1993. View at Google Scholar · View at Scopus
  122. R. G. Miller, K. R. Sharma, G. K. Pavlath et al., “Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study,” Muscle Nerve, vol. 20, no. 4, pp. 469–478, 1997. View at Google Scholar
  123. D. Skuk, M. Goulet, B. Roy et al., “First test of a “high-density injection” protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up,” Neuromuscular Disorders, vol. 17, no. 1, pp. 38–46, 2007. View at Publisher · View at Google Scholar · View at Scopus
  124. D. Charron, C. Suberbielle-Boissel, and R. Al-Daccak, “Immunogenicity and allogenicity: a challenge of stem cell therapy,” Journal of Cardiovascular Translational Research, vol. 2, no. 1, pp. 130–138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  125. M. Drukker and N. Benvenisty, “The immunogenicity of human embryonic stem-derived cells,” Trends in Biotechnology, vol. 22, no. 3, pp. 136–141, 2004. View at Publisher · View at Google Scholar · View at Scopus
  126. D. Charron, C. Suberbielle-Boissel, R. Tamouza, and R. Al-Daccak, “Anti-HLA antibodies in regenerative medicine stem cell therapy,” Human Immunology, vol. 73, no. 12, pp. 1287–1294, 2012. View at Publisher · View at Google Scholar
  127. M. R. Clatworthy, M. Espeli, N. Torpey, and K. G. C. Smith, “The generation and maintenance of serum alloantibody,” Current Opinion in Immunology, vol. 22, no. 5, pp. 669–681, 2010. View at Publisher · View at Google Scholar · View at Scopus
  128. F. Li, M. E. Atz, and E. F. Reed, “Human leukocyte antigen antibodies in chronic transplant vasculopathy-mechanisms and pathways,” Current Opinion in Immunology, vol. 21, no. 5, pp. 557–562, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. R. Al-Daccak, N. Mooney, and D. Charron, “MHC class II signaling in antigen-presenting cells,” Current Opinion in Immunology, vol. 16, no. 1, pp. 108–113, 2004. View at Publisher · View at Google Scholar · View at Scopus
  130. G. Barbieri, E. Rimini, and M. A. Costa, “Effects of human leukocyte antigen (HLA)-DR engagement on melanoma cells,” International Journal of Oncology, vol. 38, no. 6, pp. 1589–1595, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. N. Bertho, V. M. Blancheteau, N. Setterblad et al., “MHC class II-mediated apoptosis of mature dendritic cells proceeds by activation of the protein kinase C-δ isoenzyme,” International Immunology, vol. 14, no. 8, pp. 935–942, 2002. View at Google Scholar · View at Scopus
  132. A. Asakura and M. A. Rudnicki, “Side population cells from diverse adult tissues are capable of in vitro hematopoietic differentiation,” Experimental Hematology, vol. 30, no. 11, pp. 1339–1345, 2002. View at Publisher · View at Google Scholar · View at Scopus
  133. R. Benchaouir, M. Meregalli, A. Farini et al., “Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice,” Cell Stem Cell, vol. 1, no. 6, pp. 646–657, 2007. View at Publisher · View at Google Scholar · View at Scopus
  134. G. Cossu and P. Bianco, “Mesoangioblasts - Vascular progenitors for extravascular mesodermal tissues,” Current Opinion in Genetics and Development, vol. 13, no. 5, pp. 537–542, 2003. View at Publisher · View at Google Scholar · View at Scopus
  135. M. Dezawa, H. Ishikawa, Y. Itokazu et al., “Developmental biology: bone marrow stromal cells generate muscle cells and repair muscle degeneration,” Science, vol. 309, no. 5732, pp. 314–317, 2005. View at Publisher · View at Google Scholar · View at Scopus
  136. M. J. Doherty, B. A. Ashton, S. Walsh, J. N. Beresford, M. E. Grant, and A. E. Canfield, “Vascular pericytes express osteogenic potential in vitro and in vivo,” Journal of Bone and Mineral Research, vol. 13, no. 5, pp. 828–838, 1998. View at Publisher · View at Google Scholar · View at Scopus
  137. M. Gavina, M. Belicchi, B. Rossi et al., “VCAM-1 expression on dystrophic muscle vessels has a critical role in the recruitment of human blood-derived CD133+ stem cells after intra-arterial transplantation,” Blood, vol. 108, no. 8, pp. 2857–2866, 2006. View at Publisher · View at Google Scholar · View at Scopus
  138. Z. Qu-Petersen, B. Deasy, R. Jankowski et al., “Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration,” The Journal of Cell Biology, vol. 157, no. 5, pp. 851–864, 2002. View at Publisher · View at Google Scholar · View at Scopus
  139. B. G. Galvez, M. Sampaolesi, S. Brunelli et al., “Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration ability,” The Journal of Cell Biology, vol. 174, no. 2, pp. 231–243, 2006. View at Publisher · View at Google Scholar · View at Scopus
  140. Y. Torrente, G. Camirand, F. Pisati et al., “Identification of a putative pathway for the muscle homing of stem cells in a muscular dystrophy model,” The Journal of Cell Biology, vol. 162, no. 3, pp. 511–520, 2003. View at Publisher · View at Google Scholar · View at Scopus
  141. A. J. Friedenstein, U. F. Gorskaja, and N. N. Kulagina, “Fibroblast precursors in normal and irradiated mouse hematopoietic organs,” Experimental Hematology, vol. 4, no. 5, pp. 267–274, 1976. View at Google Scholar · View at Scopus
  142. C. De Bari, F. Dell'Accio, P. Tylzanowski, and F. P. Luyten, “Multipotent mesenchymal stem cells from adult human synovial membrane,” Arthritis & Rheumatology, vol. 44, no. 8, pp. 1928–1942, 2001. View at Google Scholar
  143. M. J. Hoogduijn, M. J. Crop, A. M. A. Peeters et al., “Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities,” Stem Cells and Development, vol. 16, no. 4, pp. 597–604, 2007. View at Publisher · View at Google Scholar · View at Scopus
  144. D. G. Phinney and D. J. Prockop, “Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—current views,” Stem Cells, vol. 25, no. 11, pp. 2896–2902, 2007. View at Publisher · View at Google Scholar · View at Scopus
  145. K.-G. Shyu, B.-W. Wang, H.-F. Hung, C.-C. Chang, and D. T.-B. Shih, “Mesenchymal stem cells are superior to angiogenic growth factor genes for improving myocardial performance in the mouse model of acute myocardial infarction,” Journal of Biomedical Science, vol. 13, no. 1, pp. 47–58, 2006. View at Publisher · View at Google Scholar · View at Scopus
  146. S.-C. Hung, R. R. Pochampally, S.-C. Chen, S.-C. Hsu, and D. J. Prockop, “Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis,” Stem Cells, vol. 25, no. 9, pp. 2363–2370, 2007. View at Publisher · View at Google Scholar · View at Scopus
  147. K. English, F. P. Barry, and B. P. Mahon, “Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation,” Immunology Letters, vol. 115, no. 1, pp. 50–58, 2008. View at Publisher · View at Google Scholar · View at Scopus
  148. A. J. Nauta, A. B. Kruisselbrink, E. Lurvink, R. Willemze, and W. E. Fibbe, “Mesenchymal stem cells inhibit generation and function of both CD34 +-derived and monocyte-derived dendritic cells,” Journal of Immunology, vol. 177, no. 4, pp. 2080–2087, 2006. View at Google Scholar · View at Scopus
  149. S. Beyth, Z. Borovsky, D. Mevorach et al., “Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness,” Blood, vol. 105, no. 5, pp. 2214–2219, 2005. View at Publisher · View at Google Scholar · View at Scopus
  150. P. A. Sotiropoulou, S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, and M. Papamichail, “Interactions between human mesenchymal stem cells and natural killer cells,” Stem Cells, vol. 24, no. 1, pp. 74–85, 2006. View at Publisher · View at Google Scholar · View at Scopus
  151. G. M. Spaggiari, A. Capobianco, H. Abdelrazik, F. Becchetti, M. C. Mingari, and L. Moretta, “Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2,” Blood, vol. 111, no. 3, pp. 1327–1333, 2008. View at Publisher · View at Google Scholar · View at Scopus
  152. G. M. Spaggiari, A. Capobianco, S. Becchetti, M. C. Mingari, and L. Moretta, “Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation,” Blood, vol. 107, no. 4, pp. 1484–1490, 2006. View at Publisher · View at Google Scholar · View at Scopus
  153. P.-D. Johann, M. Vaegler, F. Gieseke et al., “Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity,” BMC Cancer, vol. 10, article 501, 2010. View at Publisher · View at Google Scholar · View at Scopus
  154. S. Asari, S. Itakura, K. Ferreri et al., “Mesenchymal stem cells suppress B-cell terminal differentiation,” Experimental Hematology, vol. 37, no. 5, pp. 604–615, 2009. View at Publisher · View at Google Scholar · View at Scopus
  155. A. Augello, R. Tasso, S. M. Negrini et al., “Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway,” European Journal of Immunology, vol. 35, no. 5, pp. 1482–1490, 2005. View at Publisher · View at Google Scholar · View at Scopus
  156. P. Comoli, F. Ginevri, R. MacCario et al., “Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation,” Nephrology Dialysis Transplantation, vol. 23, no. 4, pp. 1196–1202, 2008. View at Publisher · View at Google Scholar · View at Scopus
  157. A. Corcione, F. Benvenuto, E. Ferretti et al., “Human mesenchymal stem cells modulate B-cell functions,” Blood, vol. 107, no. 1, pp. 367–372, 2006. View at Publisher · View at Google Scholar · View at Scopus
  158. K. Le Blanc, I. Rasmusson, C. Götherström et al., “Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes,” Scandinavian Journal of Immunology, vol. 60, no. 3, pp. 307–315, 2004. View at Publisher · View at Google Scholar · View at Scopus
  159. K. Sato, K. Ozaki, I. Oh et al., “Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells,” Blood, vol. 109, no. 1, pp. 228–234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  160. G. Ren, J. Su, L. Zhang et al., “Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression,” Stem Cells, vol. 27, no. 8, pp. 1954–1962, 2009. View at Publisher · View at Google Scholar · View at Scopus
  161. G. Ren, L. Zhang, X. Zhao et al., “Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide,” Cell Stem Cell, vol. 2, no. 2, pp. 141–150, 2008. View at Publisher · View at Google Scholar · View at Scopus
  162. F. Casiraghi, N. Azzollini, P. Cassis et al., “Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells,” Journal of Immunology, vol. 181, no. 6, pp. 3933–3946, 2008. View at Google Scholar · View at Scopus
  163. J. Chan, S. N. Waddington, K. O'Donoghue et al., “Widespread distribution and muscle differentiation of human fetal mesenchymal stem cells after intrauterine transplantation in dystrophic mdx mouse,” Stem Cells, vol. 25, no. 4, pp. 875–884, 2007. View at Publisher · View at Google Scholar · View at Scopus
  164. S.-W. Feng, X.-L. Lu, Z.-S. Liu et al., “Dynamic distribution of bone marrow-derived mesenchymal stromal cells and change of pathology after infusing into mdx mice,” Cytotherapy, vol. 10, no. 3, pp. 254–264, 2008. View at Publisher · View at Google Scholar · View at Scopus
  165. T. C. MacKenzie, A. F. Shaaban, A. Radu, and A. W. Flake, “Engraftment of bone marrow and fetal liver cells after in utero transplantation in MDX mice,” Journal of Pediatric Surgery, vol. 37, no. 7, pp. 1058–1064, 2002. View at Publisher · View at Google Scholar · View at Scopus
  166. E. J. Gang, R. Darabi, D. Bosnakovski et al., “Engraftment of mesenchymal stem cells into dystrophin-deficient mice is not accompanied by functional recovery,” Experimental Cell Research, vol. 315, no. 15, pp. 2624–2636, 2009. View at Publisher · View at Google Scholar · View at Scopus
  167. A. Shabbir, D. Zisa, M. Leiker, C. Johnston, H. Lin, and T. Lee, “Muscular dystrophy therapy by nonautologous mesenchymal stem cells: muscle regeneration without immunosuppression and inflammation,” Transplantation, vol. 87, no. 9, pp. 1275–1282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  168. N. M. Vieira, M. Valadares, E. Zucconi et al., “Human adipose-derived mesenchymal stromal cells injected systemically into GRMD dogs without immunosuppression are able to reach the host muscle and express human dystrophin,” Cell Transplantation, vol. 21, no. 7, pp. 1407–1417, 2012. View at Publisher · View at Google Scholar
  169. F. Mingozzi, J. J. Meulenberg, D. J. Hui et al., “AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells,” Blood, vol. 114, no. 10, pp. 2077–2086, 2009. View at Publisher · View at Google Scholar · View at Scopus
  170. A. C. Nathwani, E. G. D. Tuddenham, S. Rangarajan et al., “Adenovirus-associated virus vector-mediated gene transfer in hemophilia B,” The New England Journal of Medicine, vol. 365, no. 25, pp. 2357–2365, 2011. View at Publisher · View at Google Scholar · View at Scopus
  171. E. Breous, S. Somanathan, and J. M. Wilson, “BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver,” Molecular Therapy, vol. 18, no. 4, pp. 766–774, 2010. View at Publisher · View at Google Scholar · View at Scopus
  172. L. E. Mays, L. H. Vandenberghe, R. Xiao et al., “Adeno-associated virus capsid structure drives CD4-dependent CD8 + T cell response to vector encoded proteins,” Journal of Immunology, vol. 182, no. 10, pp. 6051–6060, 2009. View at Publisher · View at Google Scholar · View at Scopus
  173. G. Gao, L. H. Vandenberghe, M. R. Alvira et al., “Clades of adeno-associated viruses are widely disseminated in human tissues,” Journal of Virology, vol. 78, no. 12, pp. 6381–6388, 2004. View at Publisher · View at Google Scholar · View at Scopus
  174. G.-P. Gao, M. R. Alvira, L. Wang, R. Calcedo, J. Johnston, and J. M. Wilson, “Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 18, pp. 11854–11859, 2002. View at Publisher · View at Google Scholar · View at Scopus
  175. A. M. Andrés, M. J. Hubisz, A. Indap et al., “Targets of balancing selection in the human genome,” Molecular Biology and Evolution, vol. 26, no. 12, pp. 2755–2764, 2009. View at Publisher · View at Google Scholar · View at Scopus
  176. K. Tang, K. R. Thornton, and M. Stoneking, “A new approach for using genome scans to detect recent positive selection in the human genome,” PLoS Biology, vol. 5, no. 7, p. e171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  177. D. Forni, R. Cagliani, C. Tresoldi et al., “An evolutionary analysis of antigen processing and presentation across different timescales reveals pervasive selection,” PLOS Genetics, vol. 10, no. 3, Article ID e1004189, 2014. View at Google Scholar
  178. S. R. Grossman, I. Shylakhter, E. K. Karlsson et al., “A composite of multiple signals distinguishes causal variants in regions of positive selection,” Science, vol. 327, no. 5967, pp. 883–886, 2010. View at Publisher · View at Google Scholar · View at Scopus
  179. B. F. Voight, S. Kudaravalli, X. Wen, and J. K. Pritchard, “A map of recent positive selection in the human genome,” PLoS Biology, vol. 4, no. 3, p. e72, 2006. View at Publisher · View at Google Scholar · View at Scopus
  180. E. Schuller and A. Govaerts, “First results of immunotherapy with immunoglobulin G in multiple sclerosis patients,” European Neurology, vol. 22, no. 3, pp. 205–212, 1983. View at Google Scholar · View at Scopus
  181. P. Gajdos, H. Outin, D. Elkharrat et al., “High-dose intravenous gammaglobulin for myasthenia gravis,” The Lancet, vol. 1, no. 8373, pp. 406–407, 1984. View at Google Scholar · View at Scopus
  182. P. D. Donofrio, A. Berger, T. H. Brannagan III et al., “Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM Ad Hoc Committee,” Muscle and Nerve, vol. 40, no. 5, pp. 890–900, 2009. View at Publisher · View at Google Scholar · View at Scopus
  183. A. Quick and R. Tandan, “Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease,” Current Rheumatology Reports, vol. 13, no. 3, pp. 192–198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  184. M. Dall'Era and J. Davis, “CTLA4Ig: a novel inhibitor of costimulation,” Lupus, vol. 13, no. 5, pp. 372–376, 2004. View at Publisher · View at Google Scholar · View at Scopus
  185. P. Blaha, S. Bigenzahn, Z. Koporc, M. Sykes, F. Muehlbacher, and T. Wekerle, “Short-term immunosuppression facilitates induction of mixed chimerism and tolerance after bone marrow transplantation without cytoreductive conditioning,” Transplantation, vol. 80, no. 2, pp. 237–243, 2005. View at Publisher · View at Google Scholar · View at Scopus
  186. R. Calcedo and J. M. Wilson, “Humoral immune response to AAV,” Frontiers in Immunology, vol. 4, p. 341, 2013. View at Google Scholar
  187. Z. Wang, S. J. Tapscott, J. S. Chamberlain, and R. Storb, “Immunity and AAV-mediated gene therapy for muscular dystrophies in large animal models and human trials,” Frontiers in Immunology, vol. 2, p. 201, 2011. View at Google Scholar
  188. T. E. Ichim, D. T. Alexandrescu, F. Solano et al., “Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy,” Cellular Immunology, vol. 260, no. 2, pp. 75–82, 2010. View at Publisher · View at Google Scholar · View at Scopus
  189. Y. Torrente, M. Belicchi, C. Marchesi et al., “Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients,” Cell Transplantation, vol. 16, no. 6, pp. 563–577, 2007. View at Google Scholar · View at Scopus
  190. B. M. Deasy, B. M. Gharaibeh, J. B. Pollett et al., “Long-term self-renewal of postnatal muscle-derived stem cells,” Molecular Biology of the Cell, vol. 16, no. 7, pp. 3323–3333, 2005. View at Publisher · View at Google Scholar · View at Scopus
  191. B. M. Deasy, R. J. Jankowski, and J. Huard, “Muscle-derived stem cells: characterization and potential for cell-mediated therapy,” Blood Cells, Molecules, and Diseases, vol. 27, no. 5, pp. 924–933, 2001. View at Publisher · View at Google Scholar · View at Scopus
  192. M. Sampaolesi, S. Blot, G. D'Antona et al., “Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs,” Nature, vol. 444, no. 7119, pp. 574–579, 2006. View at Publisher · View at Google Scholar · View at Scopus
  193. M. Sampaolesi, Y. Torrente, A. Innocenzi et al., “Cell therapy of α-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts,” Science, vol. 301, no. 5632, pp. 487–492, 2003. View at Publisher · View at Google Scholar · View at Scopus
  194. F. S. Tedesco, H. Hoshiya, D. 'Antona G et al., “Stem cell-mediated transfer of a human artificial chromosome ameliorates muscular dystrophy,” Science Translational Medicine, vol. 3, no. 96, p. 96ra78, 2011. View at Google Scholar
  195. C. Figueiredo, D. Wedekind, T. Muller et al., “MHC universal cells survive in an allogeneic environment after incompatible transplantation,” BioMed Research International, vol. 2013, Article ID 796046, 12 pages, 2013. View at Publisher · View at Google Scholar
  196. A. Mariano, A. Henning, and R. Han, “Dysferlin-deficient muscular dystrophy and innate immune activation,” FEBS Journal, vol. 280, no. 17, pp. 4165–4176, 2013. View at Google Scholar
  197. S. A. Villalta, C. Rinaldi, B. Deng, G. Liu, B. Fedor, and J. G. Tidball, “Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype,” Human Molecular Genetics, vol. 20, no. 4, pp. 790–805, 2011. View at Publisher · View at Google Scholar · View at Scopus